SONN Stock Overview
Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 3 more risks
Sonnet BioTherapeutics Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.78 |
| 52 Week High | US$26.40 |
| 52 Week Low | US$1.08 |
| Beta | 1.12 |
| 1 Month Change | -14.56% |
| 3 Month Change | 27.14% |
| 1 Year Change | -67.11% |
| 3 Year Change | -99.72% |
| 5 Year Change | n/a |
| Change since IPO | -99.91% |
Recent News & Updates
Recent updates
Sonnet BioTherapeutics regains compliance with Nasdaq's minimum bid price requirement
Oct 04Sonnet BioTherapeutics announces 1-for-14 reverse stock split
Sep 16Sonnet gets clearance to start phase 1b/2a trial of SON-080 in Australia
Jul 22We're A Little Worried About Sonnet BioTherapeutics Holdings' (NASDAQ:SONN) Cash Burn Rate
Dec 19
Sonnet Bio issued U.S. patent for its albumin binding technology
Jun 08Sonnet shares rise after completing licensing agreement with New Life Therapeutics
May 03Sonnet BioTherapeutics reports FY results
Dec 17Shareholder Returns
| SONN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 4.7% | 1.5% | 1.2% |
| 1Y | -67.1% | 1.1% | 24.7% |
Return vs Industry: SONN underperformed the US Biotechs industry which returned 1.1% over the past year.
Return vs Market: SONN underperformed the US Market which returned 24.7% over the past year.
Price Volatility
| SONN volatility | |
|---|---|
| SONN Average Weekly Movement | 12.8% |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SONN's share price has been volatile over the past 3 months.
Volatility Over Time: SONN's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 12 | Pankaj Mohan | www.sonnetbio.com |
Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer.
Sonnet BioTherapeutics Holdings, Inc. Fundamentals Summary
| SONN fundamental statistics | |
|---|---|
| Market cap | US$5.46m |
| Earnings (TTM) | -US$14.46m |
| Revenue (TTM) | US$129.18k |
42.3x
P/S Ratio-0.4x
P/E RatioIs SONN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SONN income statement (TTM) | |
|---|---|
| Revenue | US$129.18k |
| Cost of Revenue | US$8.71m |
| Gross Profit | -US$8.58m |
| Other Expenses | US$5.88m |
| Earnings | -US$14.46m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.71 |
| Gross Margin | -6,644.90% |
| Net Profit Margin | -11,193.30% |
| Debt/Equity Ratio | 0% |
How did SONN perform over the long term?
See historical performance and comparison